DPYSL2 and early-onset autosomal dominant Alzheimer disease: Increased studies have shown that CRMP-2 could be used as a target for the treatment of various neurological disorders including Alzheimer’s disease (Cheung and Ip, 2012) and spinal cord neurons degeneration (Petratos et al., 2012).